<DOC>
	<DOC>NCT01488071</DOC>
	<brief_summary>The objective of the present study is to evaluate whether vortioxetine (10 or 20 mg/day) is at least as effective as agomelatine (25 to 50 mg/day) in patients with depressive symptoms that showed inadequate response to Serotonin Reuptake Inhibitors (SRI) antidepressants.</brief_summary>
	<brief_title>A Study of Vortioxetine (Lu AA21004) in Comparison to Agomelatine in Adults Suffering From Major Depression With Inadequate Response to Previous Medication</brief_title>
	<detailed_description />
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Vortioxetine</mesh_term>
	<mesh_term>S 20098</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<criteria>The patient is being treated with a serotonin reuptake inhibitor (SRI) antidepressant (monotherapy) that was prescribed to treat Major Depressive Episode (DSMIVTR criteria) The response to the current SRI treatment is inadequate and patient agrees to discontinue the current SRI at the baseline Montgomery Åsberg Depression Rating Scale (MADRS) total score ≥22 at the Screening Visit and Baseline The patient, if a woman, must: agree not to try to become pregnant during the study, AND use adequate, highly effective contraception The patient has any current Axis I disorders (DSMIV criteria) other than Major Depressive Disorder (MDD), General Anxiety Disorder (GAD) and Social Anxiety Disorder (SAD) The patient is at significant risk of suicide The patient is currently receiving formal psychotherapy or other psychoactive medications Other protocoldefined inclusion and exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Depression</keyword>
	<keyword>Multimodal antidepressant</keyword>
</DOC>